Roche (ROG) Diagnostics Investor Day 2025 summary

Strategic ambitions and financial guidance

• Aims to double patient access to novel high-medical value diagnostics and launch 75 new differentiated assays by 2029/2030, targeting 7–8 new assays per year.

• Diagnostics business targets mid to high single-digit sales growth, with profit growth ahead of sales; 2025 ambition is low to mid single-digit growth due to China headwinds.

• Pharma portfolio expected to deliver growth until 2028, with no patent cliff anticipated; annual generic erosion ($1–1.5B) to be offset by new and existing products.

• Five-year outlook extended to 2029, with $16.3B in additional sales expected from on-market and late-stage pipeline assets, easily covering generic erosion.

• Commitment to invest up to USD 0.55bn in a new CGM manufacturing hub in Indianapolis to support global expansion.

Business strategy and innovation focus

• Strategy centers on delivering innovative diagnostics, clinical decision support tools, and end-to-end disease management solutions.

• Focus on four key disease areas: cardiometabolic, neurology, oncology, and infectious diseases, with integrated solutions across the care continuum.

• Major launches include Accu-Chek SmartGuide CGM (2024), Cobas Mass Spec (2024), and the 2026 Roche sequencing solution (SBX/Exelios).

• Digital health is a core growth area, with AI-driven clinical decision support, lab automation, and patient empowerment tools (e.g., Navify, MySugr).

• Commitment to operational excellence, automation (Cobas Ultra), and leveraging generative AI for assay development.

Key technology and product pipeline updates

• Over 130 new tests planned by 2028, including 77 in core lab, 21 in pathology, and 34 digital solutions.

• Cobas Mass Spec: first fully automated clinical mass spectrometry system, targeting CHF 1B in annual sales by 2030, with 60+ analytes planned.

• SBX/Exelios sequencing: open, high-throughput, flexible platform launching in 2026, with early access in 2025; targets both research and clinical markets.

• Pathology: digital pathology ecosystem (Navify 3.0), multiplex IHC, and AI-powered algorithms for improved cancer diagnostics and companion diagnostics.

• Near-patient care: expansion of LIAT panels, launch of Lumira Dx handheld multimodal device, and global rollout of Accu-Chek SmartGuide CGM.